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A B S T R A C T 
 
Non-Alcoholic Fatty Liver Disease (NAFLD) is a condition that can develop into 
advanced liver disease. The NAFLD spectrum includes simple steatosis, non-alcoholic 
steatohepatitis (NASH), liver fibrosis, and liver cirrhosis to hepatocellular carcinoma. One 
of the underlying pathophysiologies is insulin resistance found in metabolic syndrome. 
People with metabolic syndrome are not always obese, and NAFLD can also be found in this 
group, known as lean NAFLD, which has different metabolic characteristics. Metabolic 
characteristics of lean NAFLD include high levels of transaminases and insulin, low insulin 
sensitivity, low fasting glucose, low necroinflammatory activity, and liver fibrosis. Some 
related factors are methionine and choline deficiency, excessive acyl-coA expression, and 
PNPLA3 gene polymorphism. Lean NAFLD is an interesting topic to discuss because 
practitioners' awareness of lean NAFLD is lower compared to obese patients. NAFLD is a 
risk factor for chronic diseases such as cardiovascular disease, kidney disease, colorectal, 
atrial fibrillation, and hypothyroidism, so it is essential to be recognized by clinicians. To 
date, there are no guidelines or recommendations that discuss specific treatments in this 
lean NAFLD population. 
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I N T R O D U C T I O N 
 Non-Alcoholic Fatty Liver 
Disease (NAFLD) is a condition that is 
increasingly being realized can develop into 
advanced liver disease. The NAFLD spectrum 
includes simple steatosis, non-alcoholic 
steatohepatitis (non-alcoholic steatohepatitis / 
NASH), liver fibrosis, liver cirrhosis, and 
hepatocellular carcinoma.[1] Patients with 
NAFLD are caused or associated with one or 
more components of metabolic syndrome, 
which is insulin resistance, impaired glucose 
and diabetes mellitus.[2] NAFLD has been 
known to be tolerance with obesity, but NAFLD 
can also be found in patients with normal BMI 
without insulin resistance or diabetes mellitus, 
which is referred to as "lean NAFLD". Lean 
NAFLD is known to have metabolic 
characteristics that are different from NAFLD-
obesity. Metabolic characteristics of lean 
NAFLD include high levels of transaminases 
and insulin, low insulin sensitivity, low fasting 
glucose, and low necro-inflammatory activity 
and liver fibrosis.[3] 
Margariti et al. in the Annals of 
Gastroenterology emphasize the fact that the 
majority of NAFLD patients in tertiary care 
have a normal BMI (lean).[4] Kim et al. show that 
the prevalence of lean NAFLD in Western 
populations is around 16%. It is almost the 
same as in Asian populations that around 15% 
to 21%.[5,6] It shows that Asians have the same 
risk of developing NAFLD as Westerners, even 
with different clinical characteristics. Lean 
NAFLD is an interesting topic to discuss 
because NAFLD is a risk factor for chronic 
diseases such as cardiovascular, kidney, 
colorectal cancer, atrial fibrillation and 
hypothyroidism.[7] Also, the lack of vigilance of 
clinicians in diagnosing lean NAFLD results in 
late intervention to patients. Recent research 
raises several important issues related to lean 
NAFLD, is lean NAFLD only a disease that is at 
risk of becoming a more severe disease or just 
the same disease with the metabolic profile of 
NAFLD without weight gain? 
Definition 
The AASLD Practice Guideline (2012) 
defines fatty liver as a condition due to excessive 
fat accumulation in the form of triglycerides 
(steatosis) in the liver (histologically> 5% of 
hepatocytes). [8] Based on the Chinese National 
Workshop on Fatty Liver Disease in 2010, the 
diagnosis of NAFLD is based on criteria:[9] 
(1) Alcohol consumption <140 grams/week 
in adult men and <70 grams/week in adult 
women 
(2) Do not suffer from hepatitis B or C, 
hepatolenticular degeneration, autoimmune 
diseases, history of total parenteral nutrition 
or consumption of hepatotoxic  
drugs (such as tamoxifen, amiodarone, sodium 
valproate, methotrexate, and glucocorticoid); 
and (3) Ultrasound examination shows fatty 
infiltration in the liver. 
Based on the 2016 EASL guidelines, the 
diagnosis of NAFLD requires the exclusion of 
alcohol consumption gram 30 grams in men and 
≥ 20 grams in women. NAFLD is closely related 
to obesity, insulin resistance, and glucose 
intolerance, but NAFLD can occur in patients 
with normal BMI without any other metabolic 
risk known as "lean NAFLD". Until now, there 
are still differences in the setting of normal BMI 
standards. In Western studies using BMI <25 kg 
/ m2 as a NAFLD lean cut-off while some studies 
in the Asia Pacific use a BMI <23 kg / m2 as a 
NAFLD lean cut-off.[10] 
Prevalence 
The prevalence of NAFLD throughout the 
world is increasing, in line with the increasing 
prevalence of obesity, hyperlipidaemia and 
diabetes mellitus in the general population. In 
Indonesia, research on NAFLD is very limited. 
Lesmana reported 17 patients with non-
alcoholic steatohepatitis (NASH) have an 
average age of 42 years, with 29% of the 
histology of the liver showing steatohepatitis 
accompanied by fibrosis. A study with a large 
sample by Hasan et al. found a prevalence of 
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non-alcoholic fatty liver (NAFLD) of 30.6%. 
Important risk factors that are reported are 
obesity, diabetes mellitus, and 
hypertriglyceridemia.[11] At RSUP dr. Kariadi 
Semarang using liver ultrasound examination 
in 2005-2009 found an increase in cases of fatty 
liver from year to year, each year is 4%, 4.5%, 
5%, 6% and 7%.[12] 
Margariti et al. in the Annals of 
Gastroenterology emphasize the fact that the 
majority of NAFLD patients in tertiary care 
have a normal BMI. The study examined 162 
patients with hepatic steatosis and found that 
every 1 of 8 NAFLD patients had a normal BMI. 
It is consistent with the results of studies in 
India about rural populations with a low 
prevalence of NAFLD, 75% of NAFLD patients 
have a BMI below 25kg / m2 and 54% without 
overweight or abdominal obesity.[4] The 
prevalence of lean NAFLD in the United States 
is 7%, in Japan 15.2 %, in Korea 12.6%, in 
Taiwan 4.2%, and in Zhejiang 7.2%. The 
majority of lean NAFLD are workers and under 
45 years old. It shows the possibility of insulin 
resistance causes an increase in fat 
accumulation in the population of Southeast 
Asia compared to Western populations even 
though BMI is within normal limits.[13] 
Pathogenesis 
NAFLD is a cause of chronic liver 
disease and is an indicator of metabolic 
syndrome, which is currently increasing in 
prevalence. NASH is one of the heavier NAFLD 
spectra defined as the presence of steatosis 
with progressive inflammation and fibrosis. 
However, the pathogenesis of NAFLD to NASH 
is not yet fully known. Conditions that are often 
associated with NASH are obesity, diabetes 
mellitus, and insulin resistance. The hypothesis 
which has so far been widely accepted is "the 
two-hit theory" proposed by Day and James.[14] 
 
Figure 1. The theory of "multiple parallel hits" [15] 
Research by the Genome-wide 
association study (GWAS) states the importance 
of the polymorphism of the patatin-like 
phospholipase 3 gene (PNPLA3) in NAFLD. 
Genetic polymorphisms can distinguish simple 
fatty with or without minimal inflammation and 
progression of fibrosis to NASH. In some cases, 
inflammation can precede steatosis and anti-
tumor necrosis factor (TNF) -α antibodies 
improve steatosis in ob/ob mice. Obesity and 
diabetes induce insulin resistance, adipocyte 
proliferation and changes in the intestinal flora. 
Adipokines such as IL-6 and TNF-α produced by 
adipocytes affect the fat component of 
hepatocytes and cause inflammation in the liver. 
Signals from Gut can be influenced by the 
consumption of trans fatty acids, fructose or 
TLR ligands. Use of free fatty acids and free 
cholesterol induces ER stress and oxidative 
stress which causes inflammation and 
fibrogenesis.[15] 
What is the pathogenesis of "lean NAFLD"?  
Several studies have been conducted to 
determine the pathogenesis of fatty liver in 
populations with normal BMI. One of the studies 
with experimental animals is mice with a 
deficiency of methionine and choline deficiency. 
The treatments above cause mice to experience 
neither insulin resistance nor  
obesity but a decrease in body weight 
and fat accumulation in the liver. It is a 
consequence of decreased beta-oxidation of 
fatty acids and decreased very low-density 
lipoproteins (VLDL), so triglycerides are 
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removed from cells.[16-17] 
In studies of mice with genetic 
modification, they produce an overexpression 
of acyl-CoA: diacylglycerol acyltransferase 2 
(DGAT2), which functions as a catalyst in the 
final step of triacylglycerol biosynthesis. In 
these mice, hepatic steatosis occurs with 
increased triglycerides, diacylglycerol, 
ceramides, and unsaturated long-chain fatty 
acyl-CoAs, without insulin resistance or 
impaired glucose metabolism. 
In humans, genetic polymorphisms are 
known to be associated with the incidence of 
hepatic steatosis without obesity or insulin 
resistance. One genetic study that is often 
investigated is the polymorphism of the 
PNPLA3 gene. Other studies show that 
polymorphisms in the I148M gene are 
associated with lipolytic activity and increased 
levels of aminotransferase without insulin 
resistance. [19] 
The Role of PNPLA3 I148M mutation in fatty 
liver disease 
Although it has been proven that 
PNPLA3 has hydrolase activity, the 
physiological role in vivo is still unclear. 
Whether the excessive expression of PNPLA3 in 
cell 293 HEK or the destruction of murine 3T3-
L1 adipocytes affects cellular triglyceride 
levels. To better explain the role of PNPLA3 in 
fatty liver disease, He et al. have just explained 
the effect of I148M substitution on localization 
and in vitro activity. Subcellular fractionation 
experiments explain that wild-type PNPLA3 is 
closely related to lipid membrane fraction and 
lipid droplet localization in Huh-7-line human 
hepatoma cells after oleate administration. 
Although there is no evidence of the 
mislocalization of the 148M PNPLA3 mutant, 
triglyceride lipase activity disappears, causing 
triglyceride accumulation in Huh-7 cells, which 
manifests as greater and greater fat droplets. 
Furthermore, acute overexpression of mutant 
protein in mice causes a doubling of the level of 
fat in the liver. However, overexpression of 
wild-type protein fails to reduce liver fat levels 
in vivo. In line with findings from population 
studies, expression of the mutant protein was 
not related to differences in levels of free fatty 
acids, phospholipids or free cholesterol in rats. 
[19] 
Besides, to work as a lipase, PNPLA3 
have acylglycerols transacetylase activity, 
including the conversion of fatty acids to 
monoacylglycerol and diacylglycerol. However, 
it has not been proven yet in vitro. The actual 
role of PNPLA3 may differ from tissue to tissue, 
and it remains unclear whether the main effect 
on the liver is to hydrolyse triglycerides or 
transfer of fatty acids. [19] 
In addition to gene polymorphisms, the 
research of Visser ME et al. Shows that the 
condition of hypobetalipoproteinemia is 
associated with severe NAFLD events without 
being accompanied by an increased metabolic 
risk.[20] 
Role of Insulin Resistance in lean NAFLD 
The cause of NAFLD in patients with 
normal BMI and without metabolic risk factors 
is not yet fully known. The underlying 
pathogenesis is multi-factorial in which genetic 
and dietary factors are associated with the 
development of lean NAFLD even without 
metabolic abnormalities. Research in Japan 
shows that diets high in cholesterol and low in 
polyunsaturated fatty acids are higher in lean 
NAFLD patients than controls, and high 
consumption of canned drinks and meat is 
associated with an increased risk of NAFLD, 
independent of BMI.[4] 
Regardless of dietary habits, NAFLD was 
found to be associated with insulin resistance, 
independent of BMI. The lack of evaluation of 
serum insulin levels and insulin resistance is a 
drawback in this study. Still, other studies have 
shown that insulin resistance is found in lean 
NAFLD even without other metabolic 
syndromes. Since it is known that insulin 
resistance levels and the prevalence of 
metabolic syndrome have increased from lean 
to overweight or obese, this has led to the 
assumption that NAFLD is the first consequence 
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of insulin resistance before progressing to 
clinical metabolic abnormalities.[4] 
Although NAFLD has a strong 
relationship with insulin resistance, this is not 
found in all cases. Review of Tilg and Moschen 
mentions that inflammation is the beginning of 
hepatic steatosis. In the review, the authors 
mention that steatosis is a "bystander 
phenomenon" and not a cause of inflammation, 
adopting the multiple hits hypothesis in 
explaining the pathogenesis of NAFLD. It is in 
line with Sanyal's research which showed a 
significant improvement in the liver histology 
of NAFLD patients who were given Vitamin E 
(antioxidant agent), without changing the level 
of insulin resistance. These data open up 
knowledge of the mechanisms associated with 
the development of hepatic and inflammatory 
steatosis, which may be applicable to lean 
NAFLD.[4] 
Hyperinsulinaemic-euglycaemic clamp 
studies show that an increased of intrahepatic 
triacylglycerol (IHTG) is strongly associated 
with insulin resistance in the liver, skeletal 
muscle and a large percentage of liver fat. Thus,  
even though the amount of IHTG is 
slightly associated with metabolic dysfunction. 
Besides, animal studies have shown the 
accumulation of liver fat associated with insulin 
signalling in the liver through activation of the 
Cε protein kinase. This mechanism shows a 
direct relationship between liver fat and insulin 
resistance. 
Recent studies in patients with FHBL 
(Familial Hipo Beta Lipoproteinemia), 
regardless of moderate or severe hepatic 
steatosis, do not show a decrease in hepatic or 
peripheral sensitivity to insulin compared with 
controls. It indicates that the accumulation of 
triacylglycerol in the liver does not show an 
association with insulin resistance in the liver 
or peripherally. 
In basal conditions, HOMA-IR tends to 
be higher in FHBL patients compared to 
controls. It is due to the high level of basal 
insulin in patients compared to controls and is 
most likely due to a decrease in insulin 
clearance and is not caused by an increase in 
insulin secretion. It is in line with previous 
studies in normal BMI patients, where liver fat 
accumulation is associated with failure of 
insulin clearance, independent of obesity. [20] 
Insulin resistance in the liver can also not 
occur in FHBL despite severe steatosis. The 
absence of insulin resistance has been 
previously studied in experimental animals 
with hepatic steatosis. In this animal, 
diacylglycerol acetyltransferase (which is the 
final step catalytic enzyme of triacylglycerol 
synthesis) is excessive in the liver. Then, 
deletions of long-chain fatty acid elongase 
family member 6 (ELOVL6) (which is a 
microsomal enzyme involved in elongation of 
fatty acids), deletion of transfer proteins 
triacylglycerol (responsible for adding 
triacylglycerol-rich lipoproteins and inhibiting 
hepatic fatty acid oxidation). All of which are 
associated with induction of hepatic steatosis 
with or without hepatic and hepatic 
resistance.[20] 
In the study of Visser ME et al., hepatic 
steatosis in FHBL may be the result of the 
accumulation of harmless triacylglycerols, 
where NAFLD is the accumulation of toxic lipid 
metabolites that cause insulin resistance. In this 
study, NEFA concentrations in circulation did 
not differ between FHBL and controls. 
Moreover, the relationship between hepatic 
steatosis and insulin resistance may be related 
to genetics. Such APOC3 polymorphisms are 
known to be associated with NAFLD and insulin 
resistance, whereas a single nucleotide 
polymorphism of rs738409 in PNPLA3 is 
associated with an increase in liver fat without 
insulin resistance. 
However, recent research not adequately 
addresses the mechanism of the relationship 
between hepatic steatosis and insulin resistance 
completely. Hepatic steatosis is possible as a 
result of insulin resistance in the liver and 
peripheral. This study shows a unique model of 
severe fatty liver disease that is not associated 
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with hepatic or peripheral insulin resistance. 
Although this study is unable to explain the 
exact mechanism underlying the complex 
relationship between hepatic steatosis and 
insulin resistance, further research is needed 
that focuses on cohort hepatic steatosis. 
Factors related to LEAN NAFLD 
Margariti et al. in the Annals of 
Gastroenterology emphasize the fact that the 
majority of NAFLD patients in tertiary care 
have a normal (lean) BMI. The study examined 
162 patients with hepatic steatosis and found 
that every 1 in 8 NAFLD patients had a normal 
BMI. One explanation for the presence of 
ectopic fat in the liver in subjects with normal 
BMI can be analogous to the metabolic system 
of obese patients but occurs in subjects with 
normal BMI, which occurs in 5% of the western 
population.[4] 
Research in the Japanese population 
shows that weight gain in adulthood is a strong 
predictor of the NAFLD in men.[13] A 10 kg 
increase in body weight since age 20 is 
significantly associated with fatty liver 
regardless of sex.[21] Pelvic circumference is 
independently and significantly related to 
NAFLD in non-obese (Male: OR 1.11, Female: 
OR 1.05). Body fat percentage was 
independently and significantly related to 
NAFLD in non-obese (Male: OR 1.13). Pelvic 
circumference and body fat percentage are 
predictors of NAFLD in the Japanese 
population.[13] 
In the Chinese population, lean NAFLD 
has different metabolic characteristics than 
overweight-obese patients. The NAFLD lean 
group had lower blood glucose, blood pressure, 
cholesterol levels, insulin resistance, and lower 
haemoglobin than the overweight-obese group. 
Subjects with normal BMI tend to suffer from 
diabetes, hypertension and metabolic 
syndrome when accompanied by NAFLD.[7] 
Thus, lean NAFLD is a more dangerous 
condition than NAFLD with overweight-
obesity. 
Previous studies mention lean NAFLD 
patients have greater visceral adipose tissue 
than overweight and obese patients. The 
research of Bhat G et al. also found that an 
increase in insulin resistance was 
proportionally associated with an increase in 
waist circumference (central obesity), this 
indicates that central obesity was more related 
to insulin resistance than BMI. Lean NAFLD may 
be an initial phase of metabolic syndrome, and 
increased waist circumference and BMI are the 
result of an increase in obesity and are a 
complication in patients in this study.[22] 
Margariti et al. showed that increased 
waist circumference in 1/3 lean NAFLD, 
metabolic syndrome in 1/5 lean NAFLD and 
more than ½ lean NAFLD met one of the 
metabolic syndrome criteria.[4] It is 
questionable whether patients with lean NAFLD 
have metabolic syndrome subclinical with 
ectopic fat as the first manifestation. It is 
interesting to be evaluated further, especially 
how the risk of metabolic disorders, insulin 
resistance or diabetes, cardiovascular events 
and progression to advanced liver disease in 
patients with lean NAFLD. 
The study of Margariti et al. also has 
some limitations, the diagnosis of NAFLD is not 
carried out uniformly to all patients, some are 
diagnosed by ultrasonography and some by 
liver biopsy which is a standard.[4] 
Ultrasonography is accurate in moderate to 
severe steatosis with a sensitivity of 85% and 
specificity of 94%.[23] It allows milder hepatic 
steatosis in lean patients compared to obesity, 
which has been established in obese patients 
with positive ultrasonography that is enough to 
make the diagnosis and in lean patients the 
limits for liver biopsy can be lower. 
The WHO expert consultation said that 
most Asians have a higher percentage of body 
fat compared to whites regardless of age, sex, 
and BMI. Asians with risk factors for type 2 
diabetes and cardiovascular disease show a 
large proportion even though WHO uses BMI 
with a cut-off below 25 kg / m2.[24] 
Feng et al. reported that subjects with 
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normal BMI tended to suffer from diabetes, 
hypertension and metabolic syndrome if they 
had NAFLD, this suggests that normal BMI 
subjects with NAFLD should be monitored  
more closely than overweight-obese subjects 
with NAFLD.[7] 
Management of NAFLD 
The management of patients with 
NAFLD consists of therapy for liver disease as 
well as accompanying metabolic syndromes 
such as hyperlipidemia, obesity, insulin 
resistance, and diabetes mellitus. Based on the 
2012 AASLD Practice Guideline, the modalities 
of NAFLD therapy include: [8] 
1. Lifestyle modification: general weight loss can 
reduce hepatic steatosis that can be achieved 
with a hypocaloric diet and/or a combination 
with physical activity. The recommended 
exercise program is 2-3x / week for 30-60 
minutes over a 6-12-week period. A weight loss 
of 3-5% can improve steatosis, but a reduction 
of up to 10% may be needed to improve 
necroinflammation. 
2. Insulin sensitizing agents: metformin has been 
shown to have no significant effect on liver 
histology and is not recommended as a specific 
therapy for NASH. Pioglitazone can be used in 
patients with liver biopsy showing NASH. 
However, the safety and efficacy of pioglitazone 
in the long term has never been studied. 
3. Antioxidants: Vitamin E at a dose of 800IU / day 
can improve liver histology in non-diabetic 
patients with liver biopsy showing NASH. 
4. UDCA is not recommended for NAFLD or NASH. 
5. Statins are not recommended as a specific 
treatment for NASH, but statins are used as a 
therapy for dyslipidemia in patients with 
NAFLD or NASH. 
6. Foregut bariatric surgery is not contraindicated 
in obese patients with NAFLD or NASH. 
Management of lean NAFLD 
Until now, there has been no 
recommendation of appropriate therapy for 
patients with lean NAFLD, whether diet and 
exercise are still useful in NAFLD patients with 
a normal BMI are still in further research. 
Recent research has found that new lifestyle 
changes can prevent the development of type 2 
diabetes. As is known, type 2 diabetes is an 
important consequence of severe insulin 
resistance, and NAFLD is an initial consequence 
of insulin resistance, so lifestyle modification at 
an early stage (lean NAFLD) is possible to 
inhibit progression to NASH and irreversible 
liver fibrosis.[22] However, this remains to be 
analyzed with prospective studies. 
Monitoring 
Oniki K et al. in a Japanese population 
with an observation duration of 5.5 ± 1.1 years 
showed the Patatin-like Phospholipase3 
(PNPLA3) G / G genotype in normal BMI 
subjects was associated with a risk of NAFLD 
(OR 3.06; 95% CI 1.11-8.43, p <0.05) and 
decreased eGFR (partial regression coefficients 
(SE) -3.26 (1.24), p <0.05).[10] It shows that 
subjects with normal BMI status accompanied 
by PNPLA3 G / G genotypic careers should be 
monitored more closely for NAFLD events, 
decreased kidney function, and other 
complications that arise. Information about the 
PNPLA3 genotype in normal BMI subjects is 
beneficial for prevention activities, although 
further research with large-scale subjects is 
needed to confirm the findings. 
C O N C L U S I O N 
NAFLD should be considered as a 
differential diagnosis in normal BMI patients 
with abnormal liver enzymes. NAFLD indicates 
a high risk of metabolic abnormalities and/or 
cardiovascular morbidity. The rs738409 
polymorphism in the PNPLA3 gene is a 
significant genetic factor of NAFLD and 
advanced liver disease, including hepatic 
steatosis, cirrhosis, and hepatocellular 
carcinoma. The rs738409 polymorphism is 
associated with decreased protein hydrolysis 
function and accumulation of hepatic 
triglycerides. Further research is needed to 
understand the pathogenesis, therapy, 
prognosis, and lean relationship of NAFLD with 
other diseases. 
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